---
document_datetime: 2023-09-21 20:24:51
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/tysabri-epar-all-authorised-presentations_en.pdf
document_name: tysabri-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7518381
conversion_datetime: 2025-12-25 09:42:30.393033
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form                   | Route of Administration   | Immediate Packaging        | Content (concentration)   | Pack size             |
|------------------|-------------------|------------|---------------------------------------|---------------------------|----------------------------|---------------------------|-----------------------|
| EU/1/06/346/001  | Tysabri           | 300mg      | Concentrate for solution for infusion | Intravenous use           | Vial (glass)               | 15 ml (20 mg/ml)          | 1 vial                |
| EU/1/06/346/002  | Tysabri           | 150 mg     | Solution for injection                | Subcutaneous use          | Pre-filled syringe (glass) | 1 ml (150 mg/ml)          | 2 pre-filled syringes |